Twist Bioscience (NASDAQ:TWST) Given New $33.00 Price Target at JPMorgan Chase & Co.

Twist Bioscience (NASDAQ:TWST) had its price objective decreased by JPMorgan Chase & Co. from $40.00 to $33.00 in a research report sent to investors on Tuesday morning,Benzinga reports. JPMorgan Chase & Co. currently has an underweight rating on the stock.

TWST has been the subject of a number of other reports. Guggenheim set a $50.00 price objective on shares of Twist Bioscience in a research note on Friday, March 28th. Robert W. Baird raised their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. Barclays lowered their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. Finally, Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $50.40.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $32.75 on Tuesday. The firm has a 50-day moving average of $39.02 and a two-hundred day moving average of $43.90. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -9.69 and a beta of 2.54. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience has a twelve month low of $32.63 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). The business had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. As a group, analysts expect that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Paula Green sold 918 shares of the firm’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the transaction, the senior vice president now owns 130,912 shares of the company’s stock, valued at approximately $5,355,609.92. This trade represents a 0.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 2,402 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the transaction, the chief executive officer now owns 662,692 shares in the company, valued at approximately $27,110,729.72. This trade represents a 0.36 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,137 shares of company stock worth $530,112. Corporate insiders own 3.01% of the company’s stock.

Institutional Trading of Twist Bioscience

Several large investors have recently made changes to their positions in TWST. Versant Capital Management Inc lifted its holdings in Twist Bioscience by 547.2% in the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock worth $27,000 after purchasing an additional 580 shares during the last quarter. GAMMA Investing LLC grew its stake in Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after buying an additional 303 shares during the last quarter. Van ECK Associates Corp raised its holdings in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience during the 3rd quarter worth $34,000. Finally, Banque Transatlantique SA bought a new stake in Twist Bioscience during the fourth quarter valued at about $43,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.